News

Article

Medicaid Status May Worsen Complications After Heart Transplantation

Author(s):

Key Takeaways

  • Medicaid-insured heart transplant recipients have a higher risk of developing cardiac allograft vasculopathy (CAV) and worse survival rates, especially post-Affordable Care Act.
  • High-volume transplant centers provide better outcomes for Medicaid patients due to specialized expertise and comprehensive care, reducing CAV risk.
SHOW MORE

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

Medicaid Status May Worsen Complications After Heart Transplantation | Image Credit: Weverton Oliveira/Pexels

Credit: Weverton Oliveira/Pexels

Medicaid-insured heart transplant recipients exhibited an amplified risk of developing cardiac allograft vasculopathy (CAV) over 5 years, according to a new analysis of the link between socioeconomic status and post-transplant complications.1

Among more than 37,000 adults who received a heart transplant, those with Medicaid insurance experienced worse survival rates in that period, particularly those in the post-Affordable Care Act (ACA) era (2014-2022). These data were presented in a plenary session at the 61st Annual Meeting of the Society of Thoracic Surgeons (STS).

“CAV is a leading cause of morbidity and mortality following heart transplant. Our work demonstrates that socioeconomic disadvantage influences the risk of CAV in the months and years following this life-saving operation,” investigator Sara Sakowitz, MPH, a medical student at the David Geffen School of Medicine at UCLA, said in a statement.2

CAV can severely impact transplanted hearts and limited long-term survival, with evidence linking CAV to more than 30% of all deaths in the first 5 to 10 years after heart transplantation.3 Patient factors, including socioeconomic disadvantage and insurance status, contribute to inferior post-transplant survival rates, but the exact mechanisms are unknown, according to Sakowitz and colleagues.1

The team identified heart transplant recipients aged ≥18 in the 2004-2022 Organ Proceurement and Transplantation Network for this analysis, defining CAV as evidence of any angiographic coronary disease. Patients were stratified by insurance status into Medicaid and non-Medicaid cohorts and the study period into pre-ACA (2004-2013) and post-ACA era (2014–2022).

Institutional volume was considered in the analysis, deeming hospitals with ≥19 cases per year in the highest quartile as “High-Volume Centers.” Among a population of 37,073 identified heart transplant recipients, the analysis showed 4875 (13%) were insured by Medicaid.

Overall, Sakowitz and colleagues found the incidence of CAV was 31%. After performing risk adjustment, they found Medicaid insurance showed a significantly greater likelihood of CAV development over 5 years (hazard ratio [HR], 1.08; 95% CI, 1.01–1.16). They noted the impact greater in the post-ACA era (HR, 1.11; 95% CI, 1.02–1.21), compared with the pre-ACA era (HR, 1.07; 95% CI, 0.84–1.36).

“Although the ACA has expanded access to heart transplantation for previously uninsured patients, significant barriers to accessing longitudinal post-transplant treatment, unaffordable medications, and equitable, high-quality care remain,” Sakowitz added.2

For those patients at high-volume institutions (≥19 cases per year), Medicaid insurance demonstrated a comparable likelihood of CAV (HR, 1.04; 95% CI, 0.95–1.14) as non-Medicaid insurance. However, when considering patients at non-high-volume centers, Medicaid was linked to significantly greater CAV risk (HR, 1.14; 95% CI, 1.03–1.26).1

Overall, the analysis correlated Medicaid insurance status with worse patient (HR, 1.31; 95% CI, 1.21–1.42) and allograft survival outcomes at the 5-year mark (HR, 1.29; 95% CI, 1.19–1.39).1 Sakowitz and colleagues indicated factors at high-volume transplant centers, including comprehensive care teams and streamlined protocols, could influence these superior outcomes, calling for further investigation into outcomes for vulnerable populations post-transplantation.

“Patients treated at high-volume transplant centers often benefit from specialized expertise, comprehensive care, and robust patient support systems,” investigator Peyman Benharash, MD, a cardiothoracic surgeon at UCLA Health, said in a statement.2 “These centers are equipped with dedicated teams and streamlined protocols that ensure consistent follow-up and access to essential medications, significantly improving post-transplant outcomes and survival rates.”

References

  1. Sakowitz S, Bakhtiyar SS, Mallick S, Higgins R, Shemin R, Benharash P. Insurance-Based Disparities in Cardiac Allograft Vasculopathy Following Heart Transplantation Are Mediated by Care at High Volume Centers. The Annals of Thoracic Surgery. January 24, 2025. Accessed January 24, 2025. https://www.annalsthoracicsurgery.org/article/S0003-4975(25)00072-4/fulltext.
  2. Medicaid-insured heart transplant patients face higher risk of post-transplant complications. UCLA Health. January 24, 2025. Accessed January 24, 2025. https://www.uclahealth.org/news/release/medicaid-insured-heart-transplant-patients-face-higher-risk.
  3. Agarwal S, Parashar A, Kapadia SR, et al. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention. JACC Heart Fail. 2014;2(3):281-288. doi:10.1016/j.jchf.2014.01.003
Related Videos
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.